← Leaderboards
Vincent Joseph Venditto
University Of California, San Francisco
$2,814,311
Attributed
$3,175,707
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $688.6K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,175,707 · 5
By mechanism
R01$1,517,601 · 1
P20$563,003 · 1
R61$542,094 · 1
R56$389,899 · 1
F32$163,110 · 1
Top collaborators
- Ahmed Abdel-Latif1 shared
- David Feola1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Bruce L Miller$34,542,477
- Meyeon Park$3,628,220
- Maria Luisa Gorno Tempini$28,653,126
- Elizabeth Rose Mayeda$9,573,054
- Robert Scott Mackin$13,397,417
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseExhibitsAntibodiesCellsProteinsEvaluationImmunizationEpitopesMediatingBaseFuturePhenotypeSamplingMouse ModelInflammationImmunoregulationInnovationCharacteristicsAutoantibodiesAutoantigensFc ReceptorApolipoprotein A-IAntiinflammatory EffectCardiovascular Diseases
Grant awards (11)
Liposomal azithromycin to treat cardiac inflammation$542,094
R61 · FY2025 · HL · contact PI
Understanding the role of immune complexes between apolipoprotein A-I and IgG in atherosclerotic cardiovascular disease$375,958
R01 · FY2023 · HL · contact PI
Understanding the role of immune complexes between apolipoprotein A-I and IgG in atherosclerotic cardiovascular disease$376,067
R01 · FY2022 · HL · contact PI
Understanding the role of immune complexes between apolipoprotein A-I and IgG in atherosclerotic cardiovascular disease$376,090
R01 · FY2021 · HL · contact PI
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular disease$263,931
P20 · FY2021 · GM · contact PI
Understanding the role of immune complexes between apolipoprotein A-I and IgG in atherosclerotic cardiovascular disease$389,486
R01 · FY2020 · HL · contact PI
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular disease$299,072
P20 · FY2020 · GM · contact PI
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular disease$389,899
R56 · FY2019 · HL · contact PI
Do peptide mimetics of gp41 improve antibody-epitope interactions?$56,978
F32 · FY2014 · AI · contact PI
Do peptide mimetics of gp41 improve antibody-epitope interactions?$53,942
F32 · FY2013 · AI · contact PI
Do peptide mimetics of gp41 improve antibody-epitope interactions?$52,190
F32 · FY2012 · AI · contact PI